• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cyteir Therapeutics Inc (NQ: CYT )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 3.070 (100)
    Ask (Size) 3.140 (105)
    Prev. Close 3.020
    Today's Range N/A - N/A
    52wk Range 2.990 - 3.190
    Shares Outstanding 71,281,616
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
    From Cyteir Therapeutics
    Via Business Wire
    Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
    From Cyteir Therapeutics
    Via Business Wire

    Performance

    More News

    Read More
    Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851
    Via Spotlight Growth
    Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Crude Oil Rises Over 1%; Fed's Preferred Inflation Gauge Slows In May
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
    From Cyteir Therapeutics
    Via Business Wire
    Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
    From Cyteir Therapeutics
    Via Business Wire
    Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
    From Cyteir Therapeutics, Inc.
    Via Business Wire
    Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
    From Cyteir Therapeutics
    Via Business Wire
    Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
    From Cyteir Therapeutics
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
    Via Benzinga
    Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
    From Cyteir Therapeutics
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
    Via Benzinga
    Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
    From Cyteir Therapeutics
    Via Business Wire
    Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
    From Cyteir Therapeutics
    Via Business Wire
    5 Value Stocks In The Healthcare Sector
    Via Benzinga
    Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
    From Cyteir Therapeutics
    Via Business Wire
    Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
    From Cyteir Therapeutics
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
    Via Benzinga
    Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
    From Cyteir Therapeutics
    Via Business Wire
    Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.